The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison

Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19)

10.1111/j.1365-2141.2010.08095.x ◽

2010 ◽

Vol 149 (3) ◽

pp. 376-382 ◽

Cited By ~ 36

Author(s):

Sergio Amadori ◽

Stefan Suciu ◽

Dominik Selleslag ◽

Roberto Stasi ◽

Giuliana Alimena ◽

...

Keyword(s):

Acute Myeloid Leukaemia ◽

Randomized Trial ◽

Myeloid Leukaemia ◽

Older Patients ◽

Low Dose ◽

Phase Ii Study ◽

Gemtuzumab Ozogamicin ◽

Intensive Chemotherapy ◽

Newly Diagnosed ◽

Sustained complete remission of recurrent acute myeloid leukaemia with a single dose of gemtuzumab ozogamicin and low-dose interleukin-2 maintenance

Leukemia ◽

10.1038/sj.leu.2402594 ◽

2002 ◽

Vol 16 (9) ◽

pp. 1870-1871

Author(s):

MP Radsak ◽

HR Salih ◽

M Sökler ◽

L Kanz ◽

C Denzlinger

Keyword(s):

Single Dose ◽

Complete Remission ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Low Dose ◽

Interleukin 2 ◽

Gemtuzumab Ozogamicin ◽

A randomised comparison of the novel nucleoside analogue sapacitabine with low-dose cytarabine in older patients with acute myeloid leukaemia

Leukemia ◽

10.1038/leu.2015.38 ◽

2015 ◽

Vol 29 (6) ◽

pp. 1312-1319 ◽

Cited By ~ 24

Author(s):

A K Burnett ◽

N Russell ◽

R K Hills ◽

N Panoskaltsis ◽

A Khwaja ◽

...

Keyword(s):

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Nucleoside Analogue ◽

Older Patients ◽

Low Dose ◽

The Novel ◽

Low Dose Cytarabine ◽

A randomised evaluation of low‐dose cytosine arabinoside (ara‐C) plus tosedostat versus low‐dose ara‐C in older patients with acute myeloid leukaemia: results of the LI‐1 trial

10.1111/bjh.17501 ◽

2021 ◽

Author(s):

Mike Dennis ◽

Alan Burnett ◽

Robert Hills ◽

Ian Thomas ◽

Cono Ariti ◽

...

Keyword(s):

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Cytosine Arabinoside ◽

Older Patients ◽

Low Dose ◽

Successful treatment with low-dose gemtuzumab ozogamicin in combination chemotherapy followed by stem cell transplantation for children with refractory acute myeloid leukaemia

10.1111/j.1365-2141.2012.09192.x ◽

2012 ◽

Vol 158 (5) ◽

pp. 666-668 ◽

Cited By ~ 3

Author(s):

Nao Yoshida ◽

Hirotoshi Sakaguchi ◽

Kimikazu Matsumoto ◽

Koji Kato

Keyword(s):

Stem Cell ◽

Stem Cell Transplantation ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Cell Transplantation ◽

Successful Treatment ◽

Combination Chemotherapy ◽

Low Dose ◽

Gemtuzumab Ozogamicin ◽

Low-dose Gemtuzumab-Ozogamicin as post-consolidation therapy in elderly patients with acute myeloid leukaemia: a pilot study

10.1111/j.1365-2141.2010.08168.x ◽

2010 ◽

Author(s):

Antonella Poloni ◽

Debora Capelli ◽

Silvia Trappolini ◽

Benedetta Costantini ◽

Mauro Montanari ◽

...

Keyword(s):

Pilot Study ◽

Elderly Patients ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Low Dose ◽

Gemtuzumab Ozogamicin ◽

Consolidation Therapy ◽

Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients

10.1111/j.1365-2141.2007.06646.x ◽

2007 ◽

Vol 138 (2) ◽

pp. 186-195 ◽

Cited By ~ 29

Author(s):

Marino Clavio ◽

Luana Vignolo ◽

Alessandra Albarello ◽

Riccardo Varaldo ◽

Ivana Pierri ◽

...

Keyword(s):

Overall Survival ◽

Elderly Patients ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Low Dose ◽

Gemtuzumab Ozogamicin ◽

Historical Cohort ◽

Disease Free ◽

The addition of low-dose cytarabine to clofarabine is beneficial in older patients with acute myeloid leukaemia (AML) and myelodysplastic syndromes

Inpharma Weekly ◽

10.2165/00128413-200816590-00041 ◽

2008 ◽

Vol &NA; (1659) ◽

pp. 16

Author(s):

&NA;

Keyword(s):

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Myelodysplastic Syndromes ◽

Older Patients ◽

Low Dose ◽

Low Dose Cytarabine ◽

Cost Effectiveness of Gemtuzumab Ozogamicin in the First-Line Treatment of Acute Myeloid Leukaemia in the UK

PharmacoEconomics - Open ◽

10.1007/s41669-021-00278-3 ◽

2021 ◽

Author(s):

T. Alexander Russell-Smith ◽

James Brockbank ◽

Carla Mamolo ◽

Christopher Knight

Keyword(s):

Cost Effectiveness ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Gemtuzumab Ozogamicin ◽

Line Treatment ◽

First Line ◽

The Uk ◽

First Line Treatment ◽

Continuous drip infusion of low dose cytarabine and etoposide with granulocyte colony-stimulating factor for elderly patients with acute myeloid leukaemia ineligible for intensive chemotherapy

Hematological Oncology ◽

10.1002/hon.834 ◽

2008 ◽

Vol 26 (1) ◽

pp. 33-38 ◽

Cited By ~ 7

Author(s):

Nobuhiro Kanemura ◽

Hisashi Tsurumi ◽

Senji Kasahara ◽

Takeshi Hara ◽

Toshiki Yamada ◽

...

Keyword(s):

Elderly Patients ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Low Dose ◽

Intensive Chemotherapy ◽

Granulocyte Colony Stimulating Factor ◽

Colony Stimulating Factor ◽

Stimulating Factor ◽

Low Dose Cytarabine ◽